Lataa...
Tβ4–Ac-SDKP pathway: Any relevance for the cardiovascular system?
The last 20 years witnessed the emergence of the thymosin β4 (Tβ4)–N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) pathway as a new source of future therapeutic tools to treat cardiovascular and renal diseases. In this review article, we attempted to shed light on the numerous experimental findings...
Tallennettuna:
| Julkaisussa: | Can J Physiol Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6824425/ https://ncbi.nlm.nih.gov/pubmed/30854877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1139/cjpp-2018-0570 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|